Quick Takeaways
- VANGUARD GROUP INC filed SCHEDULE 13G/A for Avidity Biosciences Inc Common Stock (RNA).
- Disclosed ownership: 9.6%.
- Date of event: 30 Sep 2025.
VANGUARD GROUP INC - 30 Sep 2025 SCHEDULE 13G/A Report for Avidity Biosciences Inc Common Stock (RNA)
- Filing Manager
- VANGUARD GROUP INC
- Reporting Manager
- The Vanguard Group
- Security
- Avidity Biosciences Inc Common Stock
- Symbol
- RNA
- Shares outstanding
- 138,137,503 shares
- Disclosed Ownership
- 13,219,759 shares
- Ownership
- 9.6%
- Form type
- SCHEDULE 13G/A
- Filing time
- 30 Oct 2025, 14:24:31 UTC
- Date of event
- 30 Sep 2025
- SEC
- View on sec.gov
Quoteable Key Fact
"VANGUARD GROUP INC disclosed 9.6% ownership in Avidity Biosciences Inc Common Stock (RNA) on 30 Sep 2025."
What Changed
- No earlier schedule filing is available for direct comparison.
- Current filing was accepted on 30 Oct 2025, 14:24.
Why This Matters
- This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
- You can verify ownership claims directly against the original SEC filing.
Source Evidence
Backed by Schedule 13D/13G
See Original Filing
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
Reporting Managers (1)
| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| The Vanguard Group | 9.6% | 13,219,759 | 0 | 878,441 | Ashley Grim | Head of Global Fund Administration |